www.jintan.co.jp/corp/ir/uploads/ba81b1be7b38dc55c4acf0141dfe372afdf97109.pdf

Latest saved version

第87期事業報告書

This is the newest public snapshot for this URL and the best place to start reviewing the page.

Source URL

https://www.jintan.co.jp/corp/ir/uploads/ba81b1be7b38dc55c4acf0141dfe372afdf97109.pdf

About this page

This document reports on the business overview of our group for the period from April 1, 2023, to March 31, 2024. The Japanese economy is gradually recovering, but consumer spending remains weak due to rising prices. Our healthcare business shows signs of recovery, particularly with products like 'Bifina®', achieving a sales increase of 9.2% year-on-year to 12,406 million yen, and an operating profit increase of 25.8% to 716 million yen. The capsule contract business is also performing well, and we aim for growth through new technology development and rebranding efforts.